A study on upadacitinib for Chinese adults with moderate to severe ulcerative colitis
Part of Digestive system clinical trials.
This study is looking at how well the drug upadacitinib works and how safe it is for Chinese adults with moderate to severe ulcerative colitis. It is not a treatment trial, but will observe patients who are already taking upadacitinib as decided by their doctor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be a Chinese adult aged 18 years or older.
- You have been diagnosed with moderate to severe ulcerative colitis.
- Your doctor has decided to prescribe upadacitinib for you based on your condition and the local guidelines.
- You are willing to allow the study team to access your personal and health information.
- You are not currently taking part in any other interventional clinical trials.
- You have no medical reasons that would make it unsafe for you to take upadacitinib, as listed in the drug's local label.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a medication called upadacitinib for people with inflammatory bowel disease (ulcerative colitis or Crohn's). The goal is to see how well it works and if it's safe.
This study looks at how adults with Crohn's disease or ulcerative colitis are doing after taking upadacitinib (Rinvoq) for at least 12 months. It helps doctors understand treatment patterns and outcomes in real-world settings.
This study looks at people with active Crohn's disease or ulcerative colitis starting a new type of medication (anti-TNF, ustekinumab, upadacitinib, or vedolizumab), as well as people without IBD having a routine colonoscopy. It aims to collect information to better understand how these treatments work.
Researchers want to see if taking two medications together (upadacitinib and vedolizumab) works better than taking just upadacitinib alone for people with moderate to severe ulcerative colitis. This is a real-world study, meaning it looks at patients being treated in normal medical practice.
This trial tests whether two medications, vedolizumab (a biologic given by IV) and upadacitinib (a pill), work together to help people with moderate to severe ulcerative colitis. The goal is to see if this combination is safe and effective for controlling symptoms and healing the colon.
This study tests whether upadacitinib, a pill that calms the immune system, can help people hospitalized with a severe flare of ulcerative colitis. It aims to see if the drug can reduce symptoms and help you leave the hospital sooner.
Hear when a new Ulcerative Colitis trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.